MM	Multiple myeloma
SM	smoldering myeloma
MGUS	monoclonal gammopathy of undetermined significance
CRAB	hypercalcemia, renal failure, anemia, bone involvement
ISS	international staging system
B2M	beta 2 microglobulin
LDH	lactate dehydrogenase
HCT	hematopoietic cell transplantation
BSAs	bone-stimulating agents
GLOBOCAN	Global Cancer Observatory
SEER	Surveillance, Epidemiology, and End Results
FLCs	Free light chains
VRd	bortezomib, lenalidomide, dexamethasone
Rd	lenalidomide, dexamethasone
VCd also called CyBorD	bortezomib, cyclophosphamide, dexamethasone
DRd	daratumumab, lenalidomide, and dexamethasone
KRd	carfilzomib, lenalidomide, and dexamethasone
RRMM	relapsed/refractory multiple myeloma
CNS	central nervous system
IMWG	International Myeloma Working Group
OS	overall survival
PFS	progression-free survival
DSS	Durie–Salmon system
BCMA-CART	B cell maturation antigen Chimeric antigen receptor T cells